{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:10:48Z","timestamp":1791526248398,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1124\/dmd.121.000581","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T22:55:24Z","timestamp":1638572124000},"page":"798-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase"],"prefix":"10.1016","volume":"50","author":[{"given":"Yuandong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongda","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000581_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/dmd.112.047878","article-title":"Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse","volume":"41","author":"Al Saabi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1124\/dmd.113.053785","article-title":"Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation","volume":"41","author":"Bershas","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bcp.14363","article-title":"Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects","volume":"87","author":"Bian","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000581_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/1389200023337315","article-title":"Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions","volume":"3","author":"Boelsterli","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000581_bib5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.drudis.2020.07.009","article-title":"Acyl glucuronide reactivity in perspective","volume":"25","author":"Bradshaw","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.121.000581_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000581_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/00498254.2011.618954","article-title":"Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues","volume":"42","author":"Court","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000581_bib8","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1124\/dmd.108.023176","article-title":"Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans","volume":"36","author":"Dalvie","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543776.2019.1676727","article-title":"Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016\u20132019)","volume":"29","author":"Dong","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/dmd.121.000581_bib10","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1007\/s00018-019-03155-9","article-title":"Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease","volume":"76","author":"Feng","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/dmd.121.000581_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijcard.2015.08.087","article-title":"The treatment of hyperuricemia","volume":"213","author":"Gliozzi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1124\/dmd.121.000581_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","article-title":"Review: microbial transformations of human bile acids","volume":"9","author":"Guzior","year":"2021","journal-title":"Microbiome"},{"key":"10.1124\/dmd.121.000581_bib13","first-page":"125","article-title":"Molecular physiology of urate transport","volume":"20","author":"Hediger","year":"2005","journal-title":"Physiology (Bethesda)"},{"key":"10.1124\/dmd.121.000581_bib14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000581_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-016-0550-y","article-title":"Lesinurad: first global approval","volume":"76","author":"Hoy","year":"2016","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000581_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1124\/dmd.30.4.355","article-title":"Atypical kinetic profiles in drug metabolism reactions","volume":"30","author":"Hutzler","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11926-016-0587-7","article-title":"Urate handling in the human body","volume":"18","author":"Hyndman","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1124\/dmd.121.000581_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/ph11020051","article-title":"Side effects and interactions of the xanthine oxidase inhibitor febuxostat","volume":"11","author":"Jordan","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/dmd.121.000581_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/dmd.121.000581_bib20","first-page":"654","article-title":"URAT1 inhibition by ALPK1 is associated with uric acid homeostasis","volume":"56","author":"Kuo","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/dmd.121.000581_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3961\/jpmph.2012.45.3.181","article-title":"Association between serum uric acid level and metabolic syndrome","volume":"45","author":"Lee","year":"2012","journal-title":"J Prev Med Public Health"},{"key":"10.1124\/dmd.121.000581_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.017","article-title":"Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: a focus on substrate inhibition","volume":"169","author":"Leow","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000581_bib23","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/dmd.121.000581_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40620-014-0082-z","article-title":"Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling","volume":"27","author":"Liu","year":"2014","journal-title":"J Nephrol"},{"key":"10.1124\/dmd.121.000581_bib25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1124\/dmd.107.014753","article-title":"Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2\/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics","volume":"35","author":"Ma","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","article-title":"Regulation of uric acid metabolism and excretion","volume":"213","author":"Maiuolo","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1124\/dmd.121.000581_bib27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/dmd.119.086546","article-title":"Identification of novel metabolites of vildaglipin in rats: thiazoline-containing thiol adducts formed via cysteine or glutathione conjugation","volume":"47","author":"Mizuno","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib28","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/dmd.121.000581_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development","volume":"30","author":"Oda","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000581_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.121.000581_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bmcl.2015.12.040","article-title":"Discovery of potent and orally bioavailable inhibitors of human uric acid transporter 1 (hURAT1) and binding mode prediction using homology model","volume":"26","author":"Peng","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/dmd.121.000581_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.autrev.2012.07.024","article-title":"Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets","volume":"12","author":"Punzi","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1124\/dmd.121.000581_bib33","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1124\/dmd.115.063271","article-title":"Glucuronidation of OTS167 in humans is catalyzed by UDP-glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10","volume":"43","author":"Ram\u00edrez","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000581_bib35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/dmd.121.000581_bib36","doi-asserted-by":"crossref","first-page":"20148","DOI":"10.1038\/srep20148","article-title":"The effects of URAT1\/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout\/hyperuricemia progression","volume":"6","author":"Sakiyama","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.121.000581_bib37","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1124\/dmd.110.034173","article-title":"Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide","volume":"38","author":"Sawamura","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000581_bib38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2008.01.030","article-title":"Uric acid and the development of metabolic syndrome in women and men","volume":"57","author":"Sui","year":"2008","journal-title":"Metabolism"},{"key":"10.1124\/dmd.121.000581_bib39","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/molecules21111543","article-title":"Discovery of a flexible triazolylbutanoic acid as a highly potent uric acid transporter 1 (URAT1) inhibitor","volume":"21","author":"Tian","year":"2016","journal-title":"Molecules"},{"key":"10.1124\/dmd.121.000581_bib40","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/jf60195a042","article-title":"Excreted metabolites of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane in the mouse and hamster","volume":"22","author":"Wallcave","year":"1974","journal-title":"J Agric Food Chem"},{"key":"10.1124\/dmd.121.000581_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4604","article-title":"An LC-MS\/MS method for quantification of HR011303, a novel highly selective urate transporter 1 inhibitor in beagle dogs and the application to a pharmacokinetic study","volume":"33","author":"Wang","year":"2019","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.121.000581_bib42","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/mol.107.036178","article-title":"Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity","volume":"72","author":"Wei","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000581_bib43","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41401-020-00547-7","article-title":"Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans","volume":"42","author":"Zheng","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/dmd.121.000581_bib44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11906-013-0391-y","article-title":"Uric acid, hypertension, and cardiovascular and renal complications","volume":"15","author":"Zoccali","year":"2013","journal-title":"Curr Hypertens Rep"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:53:56Z","timestamp":1739955236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624008134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0090955624008134"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000581","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}